Skip to main content

Table 3 Multivariate analyses of progression free-survival and overall survival between Del-19and L858R (n = 78)

From: Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer

Covariate Progression-free survival
Hazard ratio 95% CI p-value
 Age (<65 vs ≥65) 1.13 0.89–1.42 0.31
 Gender (Male vs Female) 0.94 0.73–1.19 0.59
 Smoking history (Never vs Ever) 0.88 0.70–1.13 0.32
 Clinical stage (IIIB, IV vs Recurrence) 1.36 0.99–1.93 0.055
EGFR mutation status (L858R vs Del-19) 0.78 0.62–0.98 *0.033
Covariate Overall survival
Hazard ratio 95% CI p-value
 Age (<65 vs ≥65) 1.21 0.87–1.70 0.25
 Gender (Male vs Female) 1.01 0.73–1.38 0.95
 Smoking history (Never vs Ever) 0.97 0.70–1.37 0.86
 Clinical stage (IIIB, IV vs Recurrence) 2.49 1.37–6.20 *0.001
EGFR mutation status (L858R vs Del-19) 1.14 0.83–1.57 0.43
  1. CI confidence interval
  2. * p < 0.05